|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial显示文摘 | Aimery de Gramont Eric Van Cutsem Hans-Joachim Schmoll Josep Tabernero Stephen Clarke Malcolm J Moore David Cunningham Thomas H Cartwright J Randolph Hecht Fernando Rivera Seock-Ah Im Gy?rgy Bodoky Ramon Salazar Frédérique Maindrault-Goebel Einat Shacham- | 2012 | Lancet Oncology2012，，12： | 3 |
| 2 | ULTRASONIC INFLUENCE OF POROSITY LEVEL ON CFRP COMPOSITE LAMINATES USING RAYLEIGH PROBE WAVES显示文摘一个沥青钩子信号比正常发生背墙回响更敏感,这被发现纵在 composites (损坏,纤维取向,低级的孔,厚度起浪,和裂缝) 向微妙的 aw 条件招手。力量和僵硬在 composites 取决于纤维取向和孔体积。合成结构的孔内容一般来说对结构的力量和表演批评。沥青钩子信号来自在哪儿的采样体积的深度与白热化的缩小的瑞利探针是相对浅的,但是深度能被增加播送并且收到的探针的分离距离增加。另外,一个方法被利用由处理 laminate 的显微图图象决定合成上篮的孔内容。一个自由软件包裹被利用处理测试样品的显微图图象。从处理方法的图象的结果与存在数据相比。横梁侧面在单向性的 CFRP 被描绘(碳纤维增强了塑料) 用沥青钩子瑞利,探针和片面沥青钩子技术被利用在自动扫描仪的帮助下生产 C 扫描图象。 | Je-Woong Park Do-Jung Kim Kwang-Hee Im Sang-Kyu Park David K.Hsu Adam H.Kite Sun-Kyu Kim Kil-Sung Lee In-Young Yang | 2008 | Acta Mechanica Solida Sinica2008，21，4： | 2 |
| 3 | Effets of grapefruit juice on the pharmacolcinetics of microcmulsion cyclospopine and its metabolite in healthy volunteers 显示文摘 | Ku YM David IM Michael F | 1998 | J Clin pharmacel1998，38，10： | 1 |
| 4 | Interferon modulation of celluiar microRNAs as an antiviral mechanism显示文摘 | Pedersen IM Cheng G Wielard S Volinia S Croce CM Chisari FV David M | | 0，，： | 1 |
| 5 | An analysis of clinical outcomes using color Doppler testieular ultrasotmd for testieular tersion 显示文摘 | Linda AB David S Ranjsv IM | 2000 | Pediatrics2000，105，3： | 1 |
| 6 | Performance of a tinned- tube evaporator optimized for different refrigerants and its effect on system efficiency 显示文摘 | DOMANSKI A DAVID Y S K IM M S | 2005 | International Journal of Refrigeration2005，2816，： | 1 |
| 7 | New insights into meticillin-resistant Staphylococcus aureus(MRSA)pathogenesis,treatment and resistance显示文摘 | Gould IM David MZ Silvano E | 2012 | Int J Antimicrob Agents2012，39，2： | 1 |
| 8 | Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical–pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial显示文摘 | Bradley J. Monk Jianmin Wang Samuel Im Richard J. Stock William A. Peters P.Y. Liu Rolland J. Barrett Jonathan S. Berek Luis Souhami Perry W. Grigsby William Gordon David S. Alberts | 2004 | Gynecologic Oncology2004，，3： | 1 |
| 9 | Advanced bladder cancer:Sta- tus of fist-line chemotherapy and the search for active agents in the second-line setting显示文摘 | David JG Matthew IM Dean FB | 2008 | Cancer2008，113，： | 1 |
| 10 | CYP3A3 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects显示文摘 | David IM Vicki LE Sharon M | 2004 | Ther Drug Monit2004，26，5： | 1 |
| 11 | Hydroprocessed rapeseed oil as a source of hydrocarbon-based biodiesel显示文摘 | Pavel ?imá?ek David Kubi?ka Gustav ?ebor Milan Pospí?il | 2008 | Fuel2008，，3： | 1 |
| 12 | High yield of same-session EUS-guided liver biopsy by 19-gauge FNA needle in patients undergoing EUS to exclude biliary obstruction显示文摘 | Stavros N. Stavropoulos Gene Y. Im Zahra Jlayer Michael D. Harris Teodor C. Pitea George K. Turi Peter F. Malet David M. Friedel James H. Grendell | 2012 | Gastrointestinal Endoscopy2012，，2： | 1 |
| 13 | Mensenteric cysts in children显示文摘 | David bliss Jr Chery IM | 1994 | Surjery1994，1115，5： | 1 |
| 14 | Dealing with energy demand:the AMP-activated protein kinase 显示文摘 | Bruce EK Ken IM David S et a1 | 1999 | Trends Biochem Sci1999，24，1： | 1 |
| 15 | Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus显示文摘AIM: To determine the safety profile of new hepatitis C virus(HCV) treatments in liver transplant(LT) recipients with recurrent HCV infection.METHODS: Forty-two patients were identified with recurrent HCV infection that underwent LT at least 12 mo prior to initiating treatment with a Sofosbuvir-based regimen during December 2013-June 2014. Cases were patients who experienced hepatic decompensation and/or serious adverse events(SAE) during or within one month of completing treatment. Controls had no evidence of hepatic decompensation and/or SAE. HIVinfected patients were excluded. Cumulative incidence of decompensation/SAE was calculated using the Kaplan Meier method. Exact logistic regression analysis was used to identify factors associated with the composite outcome. RESULTS: Median age of the 42 patients was 60 years [Interquartile Range(IQR): 56-65 years], 33%(14/42) were female, 21%(9/42) were Hispanic, and 9%(4/42) were Black. The median time from transplant to treatment initiation was 5.4 years(IQR: 2.1-8.8 years). Thirteen patients experienced one or more episodes of hepatic decompensation and/or SAE. Anemia requiring transfusion, the most common event, occurred in 62%(8/13) patients, while 54%(7/13) decompensated. The cumulative incidence of hepatic decompensation/SAE was 31%(95%CI: 16%-41%). Risk factors for decompensation/SAE included lower pre-treatment hemoglobin(OR = 0.61 per g/d L, 95%CI: 0.40-0.88, P < 0.01), estimated glomerular filtration rate(OR = 0.95 per m L/min per 1.73 m^2, 95%CI: 0.90-0.99, P = 0.01), and higher baseline serum total bilirubin(OR = 2.43 per mg/d L, 95%CI: 1.17-8.65, P < 0.01). The sustained virological response rate for the cohort of 42 patients was 45%, while it was 31% for cases.CONCLUSION: Sofosbuvir/ribavirin will continue to be used in the post-transplant population, including those with HCV genotypes 2 and 3. Management of anemia remains an important clinical challenge. | Neal Patel Kian Bichoupan Lawrence Ku Rachana Yalamanchili Alyson Harty Donald Gardenier Michel Ng David Motamed Viktoriya Khaitova Nancy Bach Charissa Chang Priya Grewal Meena Bansal Ritu Agarwal Lawrence Liu Gene Im Jennifer Leong Leona Kim-Schluger Joseph Odin Jawad Ahmad Scott Friedman Douglas Dieterich Thomas Schiano Ponni Perumalswami Andrea Branch | 2016 | World Journal of Gastroenterology2016，22，9： | 1 |
| 16 | Impacts of Curing Time and Moisture Content on Engineering Properties of Cold In-Place Recycling Mixtures Using Foamed or Emulsified Asphalt显示文摘 | Yongjoo Kim Soohyok Im Hosin David Lee | 2011 | Journal of Materials in Civil Engineering2011，23，5： | 1 |
| 17 | Current Management of Microtia:A National Survey显示文摘 | Daniel D. Im Boris Paskhover David A. Staffenberg Reza Jarrahy | | 0，，： | 1 |
| 18 | In vitro development of preimplantation porcine nuclear transfer embryos cultured in different media and gas atmospheres显示文摘 | Gi-Sun Im Liangxue Lai Zhonghua Liu Yanhong Hao David Wax Aaron Bonk Randall S Prather | 2003 | Theriogenology2003，，6： | 1 |
| 19 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 20 | Universal amplification and analysis of pathogen 16SrDNA for classification and identification of mycoplasmalike organisms显示文摘 | Lee IM Hammond RW David RW | 1993 | Phytopathilogy1993，83，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员